Table 2 Relationship between MERIT40 transcripts levels and classical clinical biological parameters in a series of 499 breast cancers.

From: WWOX binds MERIT40 and modulates its function in homologous recombination, implications in breast cancer

  

Number of patients (%)

 
 

Total population (%)

Low MERIT40 mRNA expression

High MERIT40 mRNA expression

p valuea

Total

499 (100)

436 (83.4)

63 (12.6)

 

Age

 ≤50

118 (23.6)

101 (23.2)

17 (27.0)

0.5 (NS)

 >50

381 (76.4)

335 (76.8)

46 (73.0)

SBR histological gradeb,c

 I

58 (11.9)

53 (12.5)

5 (8.1)

0.03

 II

229 (47.0)

207 (48.7)

22 (35.5)

 III

200 (41.1)

165 (38.8)

35 (56.5)

Lymph node statusd

 0

152 (30.8)

135 (31.2)

17 (27.9)

0.87 (NS)

 1–3

239 (48.4)

208 (48.0)

31 (50.8)

 >3

103 (20.9)

90 (20.8)

13 (21.3)

Macroscopic tumor sizee

 ≤25 mm

235 (48.0)

217 (50.6)

18 (29.5)

0.0021

 >25 mm

255 (52.0)

212 (49.4)

43 (70.5)

ERα status

 Negative

168 (33.7)

137 (31.4)

31 (49.2)

0.0052

 Positive

331 (66.3)

299 (68.6)

32 (50.8)

PR status

 Negative

239 (47.9)

201 (46.1)

38 (60.3)

0.035

 Positive

260 (52.1)

235 (53.9)

25 (39.7)

ERBB2 status

 Negative

381 (76.4)

341 (78.2)

40 (63.5)

0.01

 Positive

118 (23.6)

95 (21.8)

23 (36.5)

Molecular subtypes

 ER/PR− ERBB2−

96 (19.2)

78 (17.9)

18 (28.6)

0.0021

 ER/PR− ERBB2+

65 (13.0)

53 (12.2)

12 (19.0)

 ER/PR+ ERBB2−

285 (57.1)

263 (60.3)

22 (34.9)

 ER/PR+ ERBB2+

53 (10.6)

42 (9.6)

11 (17.5)

MKI67 mRNA expressionf,g

 Median

12. 5 (0.80–313)

11.7 (0.80–313)

22.4 (2.69–117)

<0.0001

  1. ER/PR hormone receptors, NS not significant.
  2. aChi-squared test.
  3. bScarff–Bloom Richardson classification.
  4. cInformation available for 487 patients.
  5. dInformation available for 494 patients.
  6. eInformation available for 490 patients.
  7. fInformation available for 429 patients.
  8. gMann–Whitney test.
  9. Significant values are shown in bold.
Back to article page